Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of oral GLPG3312 in healthy adults
NL-OMON48364Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing GLPG3312 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jan 2019; status: active, not recruiting.
02
Drugs
GLPG3312
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON48364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48364.